“Preclinical and clinical studies of the drug have demonstrated its high efficacy and safety. By the end of 2023, the third phase clinical trials were completed. Based on their results, the Russian Ministry of Health issued a certificate of permanent registration for medical use,” FMBA stated.

The Mir-19 drug was developed by scientists at the Institute of Immunology of the Russian Federal Medical and Biological Agency. The drug’s mechanism of action is based on the suppression of virus replication inside the cell. “The drug selectively suppresses the activity of vital genes of the virus without affecting the human genome.

The main components of the drug are synthetic small interfering RNA molecules, which inside the infected cell of the organism target the genome of the pathogen and contribute to its degradation.

The drug is administered by inhalation through medical nebulizers.

In December 2021, the Russian Ministry of Health registered Mir-19 as a means of targeted antiviral therapy against Covid-19. In March 2023, the drug was approved for use in outpatient practice.

jrr/arm/mem/gf